However, few medicines are approved for ATTR-wt. GlobalData estimates that vutrisiran’s entrance into the ATTR-wt market will ...

ATTR-CM is a heart disease that is often undiagnosed and can be fatal. Dr. James Ampadu, a cardiologist with Prisma Health, shares symptoms of ATTR-CM. Ian, who was diagnosed with ATTR-CM, also shares ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. ALNY announced that the European Commission (EC) has approved a label expansion of its RNAi ...

At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart failure program, he recognized this challenge almost immediately.

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

The first is known as hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy and the second is known as transthyretin amyloid cardiomyopathy (ATTR-CM). Amvuttra is an ...

In a post-hoc analysis of ATTRibute-CM, acoramidis reduced the annual frequency of CVH due to AF/AFL by 43% compared to placebo and reduced the incidence of new-onset AF/AFL by 17% in the subgroup ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

The drug, branded as Attruby in the U.S. and BEYONTTRA in Europe, showed rapid and sustained benefits for both variant and wild-type ATTR-CM patients, with noticeable improvements as early as ...